BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 21814211)

  • 1. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
    Fogari R; Zoppi A; Mugellini A; Maffioli P; Lazzari P; Derosa G
    Hypertens Res; 2011 Dec; 34(12):1321-6. PubMed ID: 21814211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
    Fogari R; Zoppi A; Salvadeo SA; Mugellini A; Lazzari P; Santoro T; Derosa G
    Hypertens Res; 2011 Apr; 34(4):509-15. PubMed ID: 21179101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
    Palma-Gamiz JL; Pêgo M; Marquez E; Pujol M; Olivan J; Alegría E; Sagastagoitia-Gorostiza JD; Gonzalez-Juanatey JR
    Clin Drug Investig; 2007; 27(6):407-17. PubMed ID: 17506591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.
    Wei F; Jia XJ; Yu SQ; Gu Y; Wang L; Guo XM; Wang M; Zhu F; Cheng X; Wei YM; Zhou ZH; Fu M; Liao YH;
    Heart; 2011 Mar; 97(6):479-84. PubMed ID: 21296780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
    Knudsen ST; Andersen NH; Poulsen SH; Eiskjaer H; Hansen KW; Helleberg K; Poulsen PL; Mogensen CE
    Am J Hypertens; 2008 Feb; 21(2):172-6. PubMed ID: 18188164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
    Willemsen JM; Rabelink TJ; Boer P; Gaillard CA
    J Hum Hypertens; 2004 Dec; 18(12):857-63. PubMed ID: 15361886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
    Cice G; Ferrara L; Tagliamonte E; Russo PE; Di Benedetto A; Iacono A
    Cardiologia; 1999 Dec; 44(12):1071-6. PubMed ID: 10687258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1.
    Sawathiparnich P; Murphey LJ; Kumar S; Vaughan DE; Brown NJ
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3867-73. PubMed ID: 12915681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of statins on angiotensin II-induced hemodynamic changes in young, mildly hypercholesterolemic men.
    Fleischmann EH; John S; Delles C; Schneider MP; Schmidt BM; Schmieder RE
    Am J Hypertens; 2004 Dec; 17(12 Pt 1):1120-6. PubMed ID: 15607618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort study in primary care.
    Yajima K; Shimada A; Hirose H; Oikawa Y; Yamada S; Meguro S; Irie J; Irie S
    Clin Drug Investig; 2009; 29(12):811-9. PubMed ID: 19888787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.
    Tsutamoto T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
    Hypertens Res; 2010 Feb; 33(2):118-22. PubMed ID: 19927151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
    Fogari R; Corradi L; Zoppi A; Lazzari P; Mugellini A; Preti P; Rinaldi A
    Am J Hypertens; 2007 Oct; 20(10):1092-6. PubMed ID: 17903693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibition and fibrinolytic balance.
    Matsumoto T; Horie M
    Hypertens Res; 2011 Apr; 34(4):448-9. PubMed ID: 21326308
    [No Abstract]   [Full Text] [Related]  

  • 15. Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors.
    Agirbasli M; Cincin A; Baykan OA
    J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):22-6. PubMed ID: 18404606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.
    Yilmaz MI; Sonmez A; Caglar K; Celik T; Yenicesu M; Eyileten T; Acikel C; Oguz Y; Yavuz I; Vural A
    Nephrology (Carlton); 2007 Apr; 12(2):147-53. PubMed ID: 17371337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients.
    Koh KK; Quon MJ; Han SH; Chung WJ; Lee Y; Shin EK
    Int J Cardiol; 2006 Mar; 108(1):96-100. PubMed ID: 16246439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
    Rosei EA; Rizzoni D; Muiesan ML; Sleiman I; Salvetti M; Monteduro C; Porteri E;
    J Hypertens; 2005 Feb; 23(2):435-44. PubMed ID: 15662233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension.
    Ke YS; Tao YY; Yang H; Yu GH
    Acta Pharmacol Sin; 2003 Apr; 24(4):337-41. PubMed ID: 12676074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
    Fujisawa T; Ikegami H; Ono M; Nishino M; Noso S; Kawabata Y; Ogihara T
    Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.